Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from BriaCell Therapeutics ( (TSE:BCT) ) is now available.
BriaCell Therapeutics has been selected for the Memorial Sloan Kettering Cancer Center’s 2025 Therapeutics Accelerator Program to advance the clinical development of its Bria-OTS+ immunotherapy. This collaboration will provide BriaCell access to MSK’s extensive resources and expertise, potentially accelerating the development and regulatory processes for Bria-OTS+, which aims to offer significant advancements in cancer treatment efficacy and safety.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$225.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care. The company is engaged in creating personalized off-the-shelf immunotherapy solutions for various cancer indications, including metastatic breast cancer and prostate cancer.
Average Trading Volume: 29,848
Technical Sentiment Signal: Sell
Current Market Cap: C$17.55M
See more data about BCT stock on TipRanks’ Stock Analysis page.